CAPTOPRIL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CAPTOPRIL

Saadav alates:

SORRES PHARMA INC

ATC kood:

C09AA01

INN (Rahvusvaheline Nimetus):

CAPTOPRIL

Annus:

50MG

Ravimvorm:

TABLET

Koostis:

CAPTOPRIL 50MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/500

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0114954002; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2014-06-20

Toote omadused

PRODUCT MONOGRAPH
CAPTOPRIL
(Captopril Tablets USP)
12.5, 25, 50 and 100 mg
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR
SORRES PHARMA INC.
DATE PREPARATION:
6111 Royalmount Ave., Suite 100
April 15, 2010
Montreal, Quebec
H4P 2T4
Control#: 137554
2
NAME OF DRUG
CAPTOPRIL
(Captopril Tablets USP)
12.5, 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Angiotensin-Converting Enzyme Inhibitor
ACTION AND CLINICAL PHARMACOLOGY
CAPTOPRIL is an angiotensin converting enzyme inhibitor used in the
treatment of hypertension
and heart failure.
The mechanism of action of captopril has not yet been fully
elucidated. It appears to lower blood
pressure and be an adjunct in the therapy of congestive heart failure
primarily through suppression of
the renin-angiotensin-aldosterone system; however, there is no
consistent correlation between renin
levels and response to the drug. Renin, an enzyme synthesized by the
kidneys, is released into the
circulation where it acts on plasma globulin substrate to produce
angiotensin I, a relatively inactive
decapeptide. Angiotensin I is then converted by angiotensin converting
enzyme (ACE) to
angiotensin II, a potent endogenous vasoconstrictor substance.
Angiotensin II also stimulates
aldosterone secretion from the adrenal cortex, thereby contributing to
sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II
by inhibition of ACE, a
peptidyldipeptide carboxy hydrolase.
ACE is identical to "bradykininase" and captopril may also interfere
with the degradation of the
vasopressor peptide, bradykinin. However, the effectiveness of
captopril in therapeutic doses
appears to be unrelated to potentiation of the actions of bradykinin.
Increased concentrations of
bradykinin or prostaglandin E
2
may also have a role in the therapeutic effect of captopril,
especially
in low-renin hypertension.
3
Inhibition of ACE results in decreased plasma angiotensin II and
increased plasma renin activity
(PRA), the latter resulting from loss of negative feedback on renin
release caused by re